Market revenue in 2023 | USD 695.0 million |
Market revenue in 2030 | USD 975.0 million |
Growth rate | 5% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 60.33% in 2023. Horizon Databook has segmented the UK inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The UK market is anticipated to grow at a lucrative growth rate during the forecast period due to increasing awareness about IBD and the presence of nonprofit organizations that support patients & healthcare professionals in diagnosis & treatment of IBD.
For instance, Crohn's and Colitis UK provides information about available treatments such as adalimumab, golimumab, infliximab, methotrexate, and tofacitinib. Moreover, in April 2022, Micro biotica announced that it received project funding from Crohn’s & Colitis Foundation for the development of therapies for IBD.
For instance, in February 2023, AbbVie announced that the UK’s MHRA approved RINVOQ, a JAK inhibitor, for the treatment of patients with moderate to severe Crohn’s disease who had an inadequate response to conventional therapy.
Horizon Databook provides a detailed overview of country-level data and insights on the UK inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into UK inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account